Search Results - "El Serafy, M."

National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care by El‐Akel, W., El‐Sayed, M. H., El Kassas, M., El‐Serafy, M., Khairy, M., Elsaeed, K., Kabil, K., Hassany, M., Shawky, A., Yosry, A., Shaker, M. K., ElShazly, Y., Waked, I., Esmat, G., Doss, W.

“…Summary Hepatitis C virus (HCV) infection is a major health problem in Egypt as the nation bears the highest prevalence rate worldwide. This necessitated…”
Get full text

Sofosbuvir‐based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt by Elsharkawy, A., Fouad, R., El Akel, W., El Raziky, M., Hassany, M., Shiha, G., Said, M., Motawea, I., El Demerdash, T., Seif, S., Gaballah, A., El Shazly, Y., Makhlouf, M. A. M., Waked, I., Abdelaziz, A. O., Yosry, A., El Serafy, M., Thursz, M., Doss, W., Esmat, G.

“…Summary Background Chronic hepatitis C virus infection is one of the most important health problems in Egypt. The Ministry of Health's National Treatment…”
Get full text

Prevalence of thyroid dysfunction among 21672 Egyptian patients with chronic HCV genotype IV by Eletreby, R, Said, M, Abdellatif, Z, Saad, Y, El Serafy, M, Yosry, A, Waked, I, Esmat, G, Doss, W

Get full text

Validation of the role of FIB-4 and APRI in the assessment of hepatic fibrosis and prediction of risky varices in Egyptian patients with chronic hepatitis C (genotype 4) by El-Nahaas, S.M, Said, M, Soliman, Z.A, Saad, Y, El-Serafy, M, Yosry, A, Waked, I, Esmat, G, Doss, W

Get full text

Real-Life Results of Sofosbuvir Based Therapy for Egyptian Patients with Hepatitis C and Advanced Fibrosis-Cirrhosis by Doss, W, Esmat, G, El-Serafy, M, El-Akel, W, Yosry, A, El-Sayed, M, Hassany, M, El-Kassas, M, Kabil, K, Waked, I

Get full text

Management of hearing impairment in children by El-Serafy, Gamal M, El-Bahnasawy, Mamdouh M, Morsy, Tosson A

“…Hearing loss in children is often a silent and hidden handicap. Children with hearing loss frequently appear to be normal, and often their handicaps are not…”
Get more information

Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response by Hamdi, N, El-Akel, W, El-Serafy, M, Esmat, G, Sarrazin, C, Abdelaziz, A I

“…To investigate the myxovirus-resistance protein A (MxA) and double-stranded RNA-activated protein kinase (PKR) genetic response to interferon (IFN) therapy in…”
Get more information

Outcome of Living Donor Liver Transplantation for Egyptian Patients With Hepatitis C (Genotype 4)-Related Cirrhosis by Yosry, A, Esmat, G, El-Serafy, M, Omar, A, Doss, W, Said, M, Abdel-Bary, A, Hosny, A, Marawan, I, El-Malt, O, Kamel, R.R, Hatata, Y, Ghali, A, Sabri, H, Kamel, S, El-Gbaly, H, Tanaka, K

“…Abstract Background Hepatitis C virus (HCV) recurrence after living donor liver transplantation (LDLT) represents a challenging issue due to universal viral…”
Get full text

Factors associated with nonresponse in a cohort of 10655 chronic hepatitis C patients treated with direct acting antivirals by Shousha, H., Said, M., Saleh, D., Saad, Y., Dabees, H., El-Serafy, M., Elsaees, K., Elshazly, Y.

Get full text

THU-288 - Factors associated with nonresponse in a cohort of 10655 chronic hepatitis C patients treated with direct acting antivirals by Shousha, H., Said, M., Saleh, D., Saad, Y., Dabees, H., El-Serafy, M., Elsaees, K., Elshazly, Y.

Get full text

Real-life experience of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin for treatment of HCV-GT4 in Egyptian patients with severe renal impairment by Omar, H., Said, M., Abdellatif, Z., Saad, Y., Dabes, H., Hamed, S., El-Serafy, M., Elsaeed, K., Elshazly, Y.

Get full text

THU-330 - Real-life experience of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin for treatment of HCV-GT4 in Egyptian patients with severe renal impairment by Omar, H., Said, M., Abdellatif, Z., Saad, Y., Dabes, H., Hamed, S., El-Serafy, M., Elsaeed, K., Elshazly, Y.

Get full text

SAT-196 - Validation of the role of FIB-4 and APRI in the assessment of hepatic fibrosis and prediction of risky varices in Egyptian patients with chronic hepatitis C (genotype 4) by El-Nahaas, S.M., Said, M., Soliman, Z.A., Saad, Y., El-Serafy, M., Yosry, A., Waked, I., Esmat, G., Doss, W.

Get full text

SAT-192 - Prevalence of thyroid dysfunction among 21672 Egyptian patients with chronic HCV genotype IV by Eletreby, R., Said, M., Abdellatif, Z., Saad, Y., El Serafy, M., Yosry, A., Waked, I., Esmat, G., Doss, W.

Get full text

SAT-165 - Real-Life Results of Sofosbuvir Based Therapy for Egyptian Patients with Hepatitis C and Advanced Fibrosis-Cirrhosis by Doss, W., Esmat, G., El-Serafy, M., El-Akel, W., Yosry, A., El-Sayed, M., Hassany, M., El-Kassas, M., Kabil, K., Waked, I.

Get full text

Chromosomal aberrations and micronucleus frequency in nurses occupationally exposed to cytotoxic drugs by Anwar, W A, Salama, S I, el Serafy, M M, Hemida, S A, Hafez, A S

“…In this study, we evaluated the effect of low level occupational exposure of nurses in a medical oncology unit in Cairo, Egypt, to anticancer drugs. Twenty…”
Get more information

Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations by Saadi, Gamal, Kalantar-Zadeh, Kamyar, Almasio, Piero, Ashuntantang, Gloria, Barsoum, Rashad, Bruchfeld, Annette, Doss, Wahid, ElFishawy, Hussein, Raziky, Maissa El, El-Serafy, Magdy, Fabrizi, Fabrizio, Hafez, Hani, Hassaballa, May, Hammady, Mona M R, Sheishaa, Hussein, Abdelaziz, Tarek S, Ulasi, Ifeoma, Zakharova, Elena, Jadoul, Michel

“…Hepatitis C virus (HCV) infection is an important cause of major morbidities including chronic liver disease, liver cancer, and acute kidney injury (AKI) as…”
Get full text

Plant proteins in milk replacers for rearing buffalo calves. I. Effect of replacing half of the milk proteins by plant proteins on the preweaning performance of buffalo calves by el-Ashry, M A, el-Serafy, A M, Zaki, A A, Soliman, H

“…In an experiment, 12 female and 8 male buffalo calves aged 3 to 4 weeks with an average of 65.2 kg live body weight were divided into 4 equal groups. Group 1…”
Get more information

Plant protein in milk replacers for rearing buffalo calves. II. Effect of replacing 75% of the milk proteins by plant proteins on the preweaning performance of buffalo calves by el-Ashry, M A, el-Serafy, A M, Zaki, A A

“…In an experiment, 9 female and 6 male buffalo calves at the age of 3 to 4 weeks were divided into 3 groups. The animals were given milk replacers in which 75%…”
Get more information

Influence of degree of fermentation on the utilization of energy from alfalfa-brome forage [Cattle] by El Serafy, A. M, Goodrich, R. D, Meiske, J. C

Get full text